Trial · NCT00089284
Results by group25
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 25
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Dose Limiting Toxicities (DLT) | 2.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | 0 | Dose-Limiting Toxicities | ||
| Dose Limiting Toxicities (DLT) | 2.5 mg/kg MGd & 6-24% Bone Marrow Involvement | 0 | Dose-Limiting Toxicities | ||
| Dose Limiting Toxicities (DLT) | 3.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | 0 | Dose-Limiting Toxicities | ||
| Dose Limiting Toxicities (DLT) | 5.0 mg/kg MGd & ≤ 5% Bone Marrow Involvement | 0 | Dose-Limiting Toxicities | ||
| Maximum Tolerated Dose (MTD) | Rituxan and 90Yttrium-Zevalin Plus MGd | 5.0 | mg/kg | ||
| Anti-lymphoma Efficacy | 2.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Complete Response (CR) | 6 | Participants | |
| Anti-lymphoma Efficacy | 2.5 mg/kg MGd & 6-24% Bone Marrow Involvement | Complete Response (CR) | 0 | Participants | |
| Anti-lymphoma Efficacy | 3.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Complete Response (CR) | 2 | Participants | |
| Anti-lymphoma Efficacy | 5.0 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Complete Response (CR) | 3 | Participants | |
| Anti-lymphoma Efficacy | 2.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Partial Response (PR) | 0 | Participants | |
| Anti-lymphoma Efficacy | 2.5 mg/kg MGd & 6-24% Bone Marrow Involvement | Partial Response (PR) | 1 | Participants | |
| Anti-lymphoma Efficacy | 3.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Partial Response (PR) | 1 | Participants | |
| Anti-lymphoma Efficacy | 5.0 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Partial Response (PR) | 1 | Participants | |
| Anti-lymphoma Efficacy | 2.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Stable Disease (SD) | 0 | Participants | |
| Anti-lymphoma Efficacy | 2.5 mg/kg MGd & 6-24% Bone Marrow Involvement | Stable Disease (SD) | 1 | Participants | |
| Anti-lymphoma Efficacy | 3.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Stable Disease (SD) | 2 | Participants | |
| Anti-lymphoma Efficacy | 5.0 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Stable Disease (SD) | 5 | Participants | |
| Anti-lymphoma Efficacy | 2.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Progressive Disease (PD) | 1 | Participants | |
| Anti-lymphoma Efficacy | 2.5 mg/kg MGd & 6-24% Bone Marrow Involvement | Progressive Disease (PD) | 0 | Participants | |
| Anti-lymphoma Efficacy | 3.5 mg/kg MGd & ≤ 5% Bone Marrow Involvement | Progressive Disease (PD) | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00089284/results